Basilea Pharmaceutica AG/€BSLN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Basilea Pharmaceutica AG
Basilea Pharmaceutica AG is a biopharmaceutical company headquartered in Basel, Switzerland. The company focuses on the research, development, and commercialization of innovative medicines, primarily in the areas of infectious diseases and oncology. Some of its key products include antifungal and antibiotic treatments like Cresemba and Zevtera, which address significant medical needs in their respective markets. Basilea was founded as a spin-off from Roche in 2000, reflecting its strong roots in pharmaceutical research. The company's strategic positioning capitalizes on its expertise in addressing drug-resistant bacterial infections and rare fungal infections, providing solutions where few alternatives exist. Basilea operates on a global scale, collaborating with international partners to expand its research and market reach.
- Ticker
- €BSLN
- Sector
- Health
- Primary listing
- XGAT
- Employees
- 200
- Headquarters
- Allschwil, Switzerland
- Website
- www.basilea.com
BSLN Metrics
BasicAdvanced
€982M
18.02
€4.35
0.32
-
Price and volume
Market cap
€982M
Beta
0.32
52-week high
€75.20
52-week low
€50.50
Average daily volume
32K
Financial strength
Current ratio
6.596
Quick ratio
5.811
Long term debt to equity
0.501
Total debt to equity
0.514
Interest coverage (TTM)
21.08%
Profitability
EBITDA (TTM)
66.124
Gross margin (TTM)
38.51%
Net profit margin (TTM)
21.17%
Operating margin (TTM)
24.20%
Effective tax rate (TTM)
10.72%
Revenue per employee (TTM)
€1,345,920
Management effectiveness
Return on assets (TTM)
13.69%
Return on equity (TTM)
39.46%
Valuation
Price to earnings (TTM)
18.024
Price to revenue (TTM)
3.595
Price to book
5.56
Price to tangible book (TTM)
5.57
Price to free cash flow (TTM)
16.137
Free cash flow yield (TTM)
6.20%
Free cash flow per share (TTM)
4.862
Growth
Revenue change (TTM)
4.74%
Earnings per share change (TTM)
-26.73%
3-year revenue growth (CAGR)
12.23%
10-year revenue growth (CAGR)
15.65%
3-year earnings per share growth (CAGR)
-3.53%
10-year earnings per share growth (CAGR)
-3.71%
Bulls say / Bears say
Cresemba sales are still accelerating: global in-market sales rose 25% to USD 817 million, triggering a USD 37.5 million European milestone payment. Basilea has raised its 2026 operating-profit forecast to CHF 115 million. (GlobeNewswire, Basilea)
Zevtera offers a second commercial growth opportunity: US hospital access is broadening, with more accounts ordering and repeat orders emerging. Its US market exclusivity runs until April 2034. (Basilea)
External funding helps Basilea advance its pipeline without relying solely on its own cash: BARDA awarded another USD 30 million for fosmanogepix after a trial-enrolment milestone, with further potential funding under the agreement. (Basilea)
Cresemba remains a major earnings driver, but its US exclusivity is expected to end in 2027 and generic entry in Europe is anticipated in 2028. Generic competition could erode royalties before newer products are established. (Edison Group)
Zevtera’s launch has yet to prove it can quickly replace revenue lost elsewhere: one analyst expects its contribution to remain modest until 2027. The antibiotic market is also constrained by stewardship practices that limit use of newer drugs. (Edison Group)
Data summarised monthly by Lightyear AI. Last updated on 3 Nov 2026.
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.